Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,212.00
Bid: 12,210.00
Ask: 12,214.00
Change: 116.00 (0.96%)
Spread: 4.00 (0.033%)
Open: 12,150.00
High: 12,266.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Cabinet minister warns of "concerning situation" as Omicron spreads

Sat, 11th Dec 2021 09:29

(Alliance News) - A booster dose sees the risk of symptomatic infection with the Omicron variant "significantly reduced", according to health officials who have urged all those eligible to make sure they get their third jab.

It comes as the experts warned the new variant could become the dominant strain in the UK by mid-December, with a Cabinet minister saying everything is being kept "under review" in terms of measures to tackle the spread.

Analysis by the UK Health Security Agency found that the AstraZeneca PLC and Pfizer Inc-BioNTech SE vaccines provided "much lower" levels of protection against symptomatic infection with Omicron compared to Delta.

But the preliminary data, which looked at 581 people with confirmed Omicron, suggested effectiveness seemed to "increase considerably" in the early period after a booster dose, giving around 70% to 75% protection against symptomatic infection.

The findings come as daily Covid-19 cases reached their highest level in almost a year and the UKHSA predicted that, if current trends continue, the UK will exceed one million infections by the end of the month.

Cabinet minister Michael Gove warned of a "deeply concerning situation" after holding a Cobra meeting on Friday afternoon to discuss the latest data and the co-ordinated response across the four nations.

The government said, as of 9 am on Friday, there had been a further 58,194 lab-confirmed Covid-19 cases in the UK.

The last time a higher daily figure was reported was on January 9, when 59,937 cases were recorded.

An additional 448 confirmed cases of the Omicron variant have been reported across the UK, bringing the total number to 1,265.

Mary Ramsay, head of immunisation at the UKHSA, said while their early data should be treated with caution, it indicates that "a few months after the second jab, there is a greater risk of catching the Omicron variant compared to Delta strain".

She added: "The data suggest this risk is significantly reduced following a booster vaccine, so I urge everyone to take up their booster when eligible."

Speaking to broadcasters, Gove said the Omicron variant is doubling every two to three days in England "and possibly even faster in Scotland".

He added that 30% of reported cases in London are the new variant, and warned that evidence suggests Omicron is "more likely" than past Covid variants to "potentially" lead to hospital admissions among the fully vaccinated.

Scotland's First Minister Nicola Sturgeon has warned of the possibility of a "tsunami of infections" from the new variant – and said she could not rule out more restrictions north of the border as a result.

But No 10 maintained that there were "no plans" to go further with measures in England, amid reports that proposals are being drawn up for a Plan C, featuring even tougher rules.

Gove said the current approach being taken is "proportionate", but acknowledged that "we absolutely do need to keep everything under review".

He said: "Action is absolutely required and, as new data comes in, we will consider what action we do require to take in the face of that data."

The Guardian reported that UK Health Secretary Sajid Javid had been given a presentation from the UKHSA earlier this week warning that even if Omicron leads to less serious disease than Delta, it still risks overwhelming the NHS with 5,000 people admitted to hospital a day.

It said the leaked advice said "stringent action" would be needed on or before December 18 if the variant's doubling time stays at 2.5 days, although the newspaper added that what such restrictions might entail were not set out other than to say measures that would bring the R number – representing the average number of people each Covid-19 positive person goes on to infect – below 1.

Professor Neil Ferguson, from Imperial College London, whose data was instrumental to the UK going into lockdown in March 2020, told The Guardian that projections suggest Omicron could "very substantially overwhelm the NHS, getting up to peak levels of admissions of 10,000 people per day".

He said such a figure could be reached "sometime in January" but added that it was based on assumptions around the variant's ability to get around existing protection, and the premise that it is similar to Delta in terms of the severity of disease it causes – something that is not yet known.

He said: "Even the best-case scenarios involve several-fold more admissions per day than we're getting at the moment – we are at about 700 right now."

New guidance expected to come into force from Wednesday will see care home residents allowed only three visitors and one essential care worker, as part of new measures to protect the sector from the spread of the new variant.

The Department of Health & Social Care said the move was "in order to balance the current Covid-19 risk and the need to keep people safe in line with clinical advice".

From Friday, in England the legal requirement to wear masks was extended to more indoor spaces including museums, galleries and community centres.

There will be a return to working from home guidance from Monday, and mandatory Covid passports for large venues from Wednesday.

The new regulations will be put to a debate and vote in the Commons next week – and with Labour's support they are certain to be approved despite the prospect of a large Conservative revolt.

Asked about the expected Tory rebellion, Gove said he is "confident" people will examine the proposals "seriously, soberly and thoughtfully", adding: "And I'm also confident people will conclude that, on balance, it is right to act."

By PA Reporters

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Apr 2024 12:55

EU regulator rules out link between weight-loss drugs and suicidal thoughts

April 12 (Reuters) - The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk's hugely popular Wegovy, are linked to suicidal thoughts, it said on Friday, ending a nine-month probe.

Read more
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.